Standard BioTools Set to Engage Investors
Standard BioTools Inc. (NASDAQ: LAB) has announced exciting participation in several influential investor conferences this November. Its management team, led by President and CEO Michael Egholm, PhD, is gearing up to share insights into the company’s transformative technologies and advancements in biomedical research.
Upcoming Conferences
This month features two major events where Standard BioTools will actively engage with investors:
UBS Global Healthcare Conference
The UBS Global Healthcare Conference on November 12 will be a key platform for the company. Michael Egholm is scheduled to present at 1:15 p.m. PT, outlining the strategic direction of Standard BioTools and its commitment to advancing healthcare solutions through innovative technologies.
Jefferies London Healthcare Conference
Subsequently, the Jefferies London Healthcare Conference from November 19 to 21 marks another significant opportunity. Egholm will deliver a corporate presentation on the first day at 8:30 a.m. GMT, emphasizing the company's role in addressing critical healthcare challenges.
Accessible Presentations
For those unable to attend in person, both conferences will provide live webcasts accessible via the Investor Relations section of the company’s website. Presentations will be archived for further accessibility, ensuring that both current and potential investors have the opportunity to stay informed.
About Standard BioTools Inc.
Standard BioTools Inc. (NASDAQ: LAB), formerly known as Fluidigm Corporation, is redefining the landscape of biomedical research. The company specializes in next-generation technologies that streamline the pathway from laboratory to better patient outcomes. Through its innovative mass cytometry and microfluidics solutions, Standard BioTools offers a reliable platform for researchers across various sectors, including oncology and immunology, to accelerate the discovery of new medicines.
Connecting with Clients and Researchers
The company empowers clinical and translational research laboratories globally, ensuring they have the necessary tools to tackle pressing health issues. By focusing on collaborations with academic institutions, government entities, and pharmaceutical organizations, Standard BioTools plays an essential role in the future of healthcare development.
To keep up with their groundbreaking work or for further inquiries, their website provides extensive resources on products, innovations, and the latest news. Standard BioTools maintains a strong social media presence, allowing users to engage and learn more through platforms like X, Facebook, LinkedIn, and YouTube.
Investor Relations
Investors can reach out to David Holmes from the Gilmartin Group LLC for inquiries. He can be contacted via email at ir@standardbio.com. Standard BioTools remains committed to transparency and open communication with its stakeholders.
Frequently Asked Questions
What is Standard BioTools focused on?
Standard BioTools focuses on developing innovative technologies to aid biomedical research, especially in areas like oncology and immunology.
Who will represent Standard BioTools at the conferences?
President and CEO, Michael Egholm, PhD, will represent the company at both conferences.
Where can I watch the investor presentations?
The presentations will be available live and archived on the Investor Relations page of the Standard BioTools website.
How does Standard BioTools impact research?
The company provides vital tools that help researchers accelerate their work, ultimately leading to improved patient outcomes.
What is the history of Standard BioTools?
Previously known as Fluidigm Corporation, Standard BioTools has evolved its business model to emphasize next-generation biomedical technologies.
